EUVIMEDEUVIMED entdecken
Crossref

The Paradoxical Influence of Hyperthermia on Progression‐Free Survival in Recurrent/Metastatic Oral Cancer Treated With Immune Checkpoint Inhibitors

Shogo Kikuta iD, Chikayuki Hattori, Yushi Abe, Kiyosato Hino, Katsuhisa Matsuo, Jingo Kusukawa

Oral Diseases · 2025

DOI: 10.1111/odi.70051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Shogo Kikuta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dental and Oral Medical Center, Kurume University School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Mouth Neoplasms, Neoplasm Recurrence, Local, Hyperthermia, Induced. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical evidence for combining hyperthermia (HT) with immune checkpoint inhibitors (ICIs) in recurrent/metastatic oral cancer (RM‐OC) is lacking. To our knowledge, this is the first study to investigate the clinical impact of this combination therapy in this specific cohort.

Methods

We retrospectively analyzed 35 patients with RM‐OC treated with ICIs. Patients receiving concurrent HT ( n = 8) were compared to those without HT ( n = 27). Progression‐free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier and Cox proportional hazards models.

Results

A significant discordance between endpoints emerged. Multivariate analysis revealed that concurrent HT was paradoxically associated with significantly worse PFS (hazard ratio, 3.06; 95% confidence interval, 1.08–8.64; p = 0.035). In stark contrast, HT had no corresponding negative impact on OS (median OS: 26.2 vs. 30.2 months; p = 0.53).

Conclusion

Concurrent HT with ICI therapy was paradoxically associated with diminished PFS without impacting OS. This critical discordance suggests that the observed radiographic progression may reflect intense, HT‐induced immune‐related inflammation (pseudoprogression) rather than true tumor progression. These findings underscore the complexity of interpreting efficacy endpoints for this novel combination therapy and highlight the need to reconsider standard response evaluation criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMouth NeoplasmsNeoplasm Recurrence, LocalHyperthermia, InducedHumansMaleFemaleRetrospective StudiesMiddle AgedAgedProgression-Free SurvivalCombined Modality TherapyAdultAged, 80 and over

Stichwörter der Autor:innen

hyperthermiaimmune checkpoint inhibitormetastaticnivolumaboral cancerpembrolizumabprognostic factorrecurrent

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Dental and Oral Medical Center, Kurume University School of Medicine, Fukuoka, Japan.
  • Department of Radiology, Kurume University School of Medicine, Kurume, Japan.

ORCID-Profile: Shogo Kikuta

Zitieren

APA

Kikuta, S., Hattori, C., Abe, Y., Hino, K., Matsuo, K., & Kusukawa, J. (2025). The Paradoxical Influence of Hyperthermia on Progression‐Free Survival in Recurrent/Metastatic Oral Cancer Treated With Immune Checkpoint Inhibitors. Oral Diseases. https://doi.org/10.1111/odi.70051

Vancouver

Kikuta S, Hattori C, Abe Y, Hino K, Matsuo K, Kusukawa J. The Paradoxical Influence of Hyperthermia on Progression‐Free Survival in Recurrent/Metastatic Oral Cancer Treated With Immune Checkpoint Inhibitors. Oral Diseases. 2025. doi:10.1111/odi.70051

BibTeX
@article{Kikuta2025,
  author = {Kikuta, Shogo and Hattori, Chikayuki and Abe, Yushi and Hino, Kiyosato and Matsuo, Katsuhisa and Kusukawa, Jingo},
  title = {The Paradoxical Influence of Hyperthermia on Progression‐Free Survival in Recurrent/Metastatic Oral Cancer Treated With Immune Checkpoint Inhibitors},
  journal = {Oral Diseases},
  year = {2025},
  doi = {10.1111/odi.70051}
}
Kostenlos starten →